Patent · US Active

Treatment of cardiometabolic disease with inhibitors of type I interferon signalling

US12410254B2 · kind B2 · utility

0Cited by

0References

11Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

Dominic SINIBALDI · Gaithersburg, US
Wendy White · Germantown, US
Michael J. Smith · Somerville, US
Kerry CASEY · Gaithersburg, US
Gabor G. ILLEI · Gaithersburg, US

Key dates

Filing date	Dec 22, 2023
Grant date	Sep 9, 2025
Priority date	—
Expiry date	Dec 22, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure relates to methods for the treatment of, or for reducing the risk for development of, a cardiometabolic in a patient using an inhibitor of type I IFN signalling.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.